The effects of vasopressin and oxytocin on methamphetamine-induced place preference behaviour in rats

Metabolic Brain Disease

Volumn 27, Issue 3, 2012, Pages 341-350

  Subiah, Cassandra O ^a   Mabandla, Musa V ^a   Phulukdaree, Alisa ^a   Chuturgoon, Anil A ^a   Daniels, Willie M U ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Conditioned place preference; Methamphetamine; Oxytocin; Vasopressin antagonist

Indexed keywords

CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NELIVAPTAN; OXYTOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; DOPAMINERGIC TRANSMISSION; LEARNING; MALE; MEMORY; NONHUMAN; PLACE REFERENCE BEHAVIOR; PROTEIN EXPRESSION; RAT;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; MALE; METHAMPHETAMINE; OXYTOCIN; RATS; RATS, SPRAGUE-DAWLEY; VASOPRESSINS;

ANIMALIA; RATTUS;

EID: 84864481846     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-012-9297-7     Document Type: Article

References (65)

1. Balazs R (2006) Trophic effect of glutamate. Curr Top Med Chem 6:961-968. doi:10.2174/156802606777323700
2. Boccia MM, Kopf SR, Baratti CM (1998) Effects of a single administration of oxytocin or vasopressin and their interactions with two selective receptor antagonists on memory storage in mice. Neurobiol Learn Mem 69:136-146. doi:http://dx.doi.org/10.1006/nlme.1997.3817
3. Buxton JA, Dove NA (2008) The burden and management of crystal meth use. Can Med Assoc J 178:1537-1539. doi:10.1503/cmaj.071234
4. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopaminemediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30:211-219. doi:10.1016/j.tins.2007.03.001
5. Carson DS, Cornish JL, Guastella AJ, Hunt GE, McGregor IS (2010) Oxytocin decreases methamphetamine self-administration, meth-amphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. Neuropharmacology 58:38-43. doi:10.1016/j.neuropharm.2009.06.018
6. Chao J, Nestler EJ (2004) Molecular neurobiology of drug addiction. Annu Rev Med 55:113-132. doi:10.1146/Annurev.Med.55.091902.103730
7. Clément P, Peeters M, Bernabe J, Denys P, Alexandre L, Giuliano F (2008) Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats. Br J Pharmacol 154:1150-1159. doi:10.1038/bjp.2008.176
8. Cui S, Bowen RC, Gu G, Hannesson DK, Yu PH, Zhang X (2001) Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. J Neurosci 21:9867-9876
9. de Wied D (1997) Neuropeptides in learning and memory processes. Behav Brain Res 83:83-90. doi:10.1016/S0166-4328
10. de Wied D, Elands J, Kovács G (1991) Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor? Proc Natl Acad Sci U S A 88:1494-1498. doi:10.1073/pnas.88.4.1494
11. DeMarco A, Dalal RM, Pai J, Aquilina SD, Mullapudi U, Hammel C, Kothari SK, Kahanda M, Liebling CNB, Patel V, Schiffer WK, Brodie JD, Dewey SL (2009) Racemic gamma vinyl-GABA (R, S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference. Synapse 63:87-94. doi:10.1002/syn.20582
12. Dempster EL, Burcescu I, Wigg K, Kiss E, Baji I, Gadoros J, Tamás Z, Kennedy JL, Vetró A, Kovacs M, Barr CL (2007) Evidence of an Association between the Vasopressin V1b Receptor Gene (AVPR1B) and childhood-onset mood disorders. Arch Gen Psychiatry 64:1189-1195. doi:10.1001/archpsyc.64.10.1189
13. Dobbs LK, Mark GP (2008) Comparison of systemic and local meth-amphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse. Neuroscience 156:700-711. doi:10.1016/j. neuroscience.2008.07.052
14. Engelmann M, Wotjak CT, Neumann I, Ludwig M, Landgraf R (1996) Behavioural consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci Biobehav Rev 20: 341-58. doi:http://dx.doi.org/10. 1016/0149-7634(95)00059-3
15. Fanselow MS, Poulos AM (2005) The neuroscience of mammalian associative learning. Annu Rev Psychol 56:207-234. doi:10.1146/annurev.psych.56.091103. 070213
16. Feifel D, Shilling PD, Belcher AM (2011) The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2011.09.004
17. Frye CA, Walf AA (2010) Oxytocin and/or steroid hormone binding globulin infused into the ventral tegmental area modulates progestogen-mediated lordosis. Neuropharmacology 58:44-49. doi:10.1016/j.neuropharm.2009.07.006
18. Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81:629-683
19. Hedges VL, Staffend NA, Meisel RL (2010) Neural mechanisms of reproduction in females as a predisposing factor for drug addiction. Front Neuroendocrinol 31:217-231. doi: 10.1016/j.yfrne.2010.02.003
20. Heinrichs M, Meinlschmidt G, Wippich W, Ehlert U, Hellhammer DH (2004) Selective amnesic effects of oxytocin on human memory. Physiol Behav 83:31-38. doi:10.1016/j.physbeh.2004.07.020
21. Herrold AA, Shen F, Graham MP, Harper LK, Specio SE, Tedford CE, Napier TC (2008) Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend 99:231-239. doi:10.1016/j.drugalc-dep. 2008.08.005
22. Holtz NA, Lozama A, Prisinzano TE, Carroll ME (2012) Reinstatement ofmethamphetamine seeking in male and female rats treated with modafinil and allopregnanolone. Drug Alcohol Depend 120:233-237. doi:10.1016/j.drugalcdep. 2011.07.010
23. Hyman SE (2005) Addiction: a disease of learning and memory 162: 1414-1422 doi:10.1176/appi.ajp.162.8.1414
24. Hyman SE, Malenka RC (2001) Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2:695-703. doi:10.1038/35094560
25. Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29:565-598. doi:10.1146/annurev.neuro.29.051605.113009
26. Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. Nature 8:844-858. doi:10.1038/nrn2234. doi:10.1038/nrn2234
27. Kelley AE (2004) Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44:161-179. doi:10.1016/j.neuron.2004.09.016
28. Klimkiewicz T (2001) Memory effects of arginine vasopressin (AVP) and [7-9] fragment of its peptide chain in rats. Acta Neurobiol Exp 61:267-276
29. Koob GF (2000) Neurobiology of addiction: toward the development of new therapies. Ann N Y Acad Sci 909:170-185. doi: 10.1111/j.1749-6632.2000.tb06682.x
30. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238. doi:10.1038/npp.2009.110
31. Kopnisky KL, Hyman SE (2002) Molecular and cellular biology of addiction. Neuropsychopharmacology: the Fifth Generation of Progress 1368-1379
32. Kovács GL, Bohus B, Versteeg DH, de Kloet ER, de Wied D (1979) Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures. Brain Res 175:303-314. doi:10.1016/0006-8993(79)91009-6
33. Kovács GL, Laczi F, Vecsernyés M, Hódi K, Telegdy G, László FA (1987) Limbic oxytocin and arginine 8-vasopressin in morphine tolerance and dependence. Exp Brain Res 65:307-311. doi:10.1007/BF00236302
34. Kovács GL, Sarnyai Z, Szabo G (1998) Oxytocin and addiction: a review. Psychoneuroendocrinology 23: 945-962 doi:http://dx.doi.org/10.1016/ S0306-4530(98)00064-X
35. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22:8951-8960
36. Lenz KM, Sengelaub DR (2010) Maternal care effects on the development of a sexually dimorphic motor system: the role of spinal oxytocin. Horm Behav 58:575-581. doi:10.1016/j.yhbeh.2010.07.010
37. Leshner AI (1997) Addiction is a brain disease, and it matters. Science 278:45-47. doi:10.1126/science.278.5335.45
38. Li S, Ren Y, Zheng J (2002) Effect of 7-nitroindazole on drug-priming reinstatement of D-methamphetamine-induced conditioned place preference. Eur J Pharmacol 443: 205-206. doi:http://dx.doi.org/10.1016/S0014-2999(02)01580-7
39. Marazziti D, Bani A, Casamassima F, Catena M, Consoli G, Gesi C, Iovieno N, Massei GJ, Muti M, Ravani L, Romano A, Roncaglia I, Scarpellini P (2006) Oxytocin: an old hormone for new avenues. Clin Neuropsychiatry 3:302-321
40. McGregor IS, Callaghan PD, Hunt GE (2008) From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use? Br J Pharmacol 154:358-368. doi:10.1038/bjp. 2008.132
41. Mizuno M, Yamada K, Maekawa N, Saito K, Seishima M, Nabeshima T (2002) CREB phosphorylation as a molecular marker of memory processing in the hippocampus for spatial learning. Behav Brain Res 133: 135-41. doi:http://dx.doi.org/10.1016/S0166-4328(01)00470-3
42. Moffett MC, Goeders NE (2007) CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats. Psychopharmacology 190:171-180. doi:10.1007/s00213-006-0625-7
43. Mueller D, Stewart J (2000) Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav Brain Res 115:39-47. doi:10.1016/S0166-4328(00)00239-4
44. Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Neuroscience 2:119-128. doi:10.1038/35053570
45. Nestler EJ (2002) Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 78:637-647. doi:10.1006/nlme.2002.4084
46. Orsini C, Izzo E, Koob GF, Pulvirenti L (2002) Blockade of nitric oxide synthesis reduces responding for cocaine self-administration during extinction and reinstatement. Brain Res 925: 133-140. doi:http://dx.doi.org/10.1016/S0006- 8993(01)03267-X
47. Pierce RC, Kumaresana V (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30:215-238. doi: 10.1016/j.neubiorev.2005.04.016
48. Plüddemann A, Flisher AJ, McKetind R, Parrye C, Lombardg C (2010) Methamphetamine use, aggressive behavior and other mental health issues among high-school students in Cape Town, South Africa. Drug Alcohol Depend 109:14-19. doi:10.1016/j.drugalcdep. 2009.11.021
49. Qi J, Yang J, Wang F, Zhao Y, Song M, Wu C (2009) Effects of oxytocin on methamphetamine-induced conditioned place preference and the possible role of glutamatergic neurotransmission in the medial prefrontal cortex of mice in reinstatement. Neuropharmacology 56:856-865. doi:10.1016/j.neuropharm.2009.01. 010
50. Roberts AJ, Koob GF (1997) The neurobiology of addiction an overview. Alcohol Health Res World 21:101-106
51. Robinson DL, Zitzman DL, Williams SK (2011) Mesolimbic dopamine transients in motivated behaviors: focus on maternal behavior. Front Psychiatr 2. doi:10.3389/fpsyt.2011.00023
52. Rogers JL, De Santis S, See RE (2008) Extended methamphetamine self-administration enhances reinstatement of drug seeking and impairs novel object recognition in rats. Psychopharmacology 199:615-624. doi:10.1007/s00213- 008-1187-7
53. Sahgal A (1984) A critique of the vasopressin-memory hypothesis. Psychopharmacology 83:215-228. doi:10.1007/BF00464785
54. Salo R, Nordahl TE, Leamon MH, Natsuakib Y, Moore CD, Waters C, Carter CS (2008) Preliminary evidence of behavioral predictors of recurrent drug-induced psychosis in meth-amphetamine abuse. Psychiatr Res 157:273-277. doi:10.1016/j.psychres.2007.04.018
55. Sarantis K, Matsokis N, Angelatou F (2009) Synergistic interactions of dopamine D1 and glutamate NMDA receptors in rat hippocampus and prefrontal cortex: involvement of ERK1/2 signaling. Neuroscience 163:1135-1145. doi:10.1016/j.neuroscience.2009.07.056
56. Shahrokh DK, Zhang T, Diorio J, Gratton A, Meaney MJ (2010) Oxytocin-dopamine interactions mediate variations in maternal behavior in the rat. Endocrinology 151:2276-2286. doi:10.1210/en.2009-1271
57. Shippenberg TS, Zapata A, Chefer VI (2007) Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116:306-321. doi:10.1016/j.pharmthera.2007.06.011
58. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu T, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Investig 113:302-309. doi:10.1172/JCI200419656
59. Tomkins DM, Sellers EM (2001) Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. CMAJ 164:817-821
60. Van Ree JM, Hijman R, Jolles J, de Wied D (1985) Vasopressin and related peptides: animal and human studies. Progr Neuro Psycho-pharmacol Biol Psychiatr 9: 551-559. doi:http://dx.doi.org/10.1016/0278-5846(85)90016-8
61. Walters CL, Kuo Y, Blendy JA (2003) Differential distribution of CREB in the mesolimbic dopamine reward pathway. J Neurochem 87:1237-1244. doi:10.1046/j.1471-4159.2003.02090.x
62. West AE, Griffith EC, Greenberg ME (2002) Regulation of transcription factors by neuronal activity. Neuroscience 3:921-931. doi:10.1046/j.1471-4159. 2003.02090.x
63. Zhou L, Zhu Y (2006) Changes of CREB in rat hippocampus, pre-frontal cortex and nucleus accumbens during three phases of morphine induced conditioned place preference in rats. J Zhejiang Univ Sci B 7:107-113. doi:10.1631/jzus. 2006.B0107
64. Zhou Y, Leri F, Cummins E, Hoeschele E, Kreek MJ (2008) Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin. Neuropsychopharmacology 33:226-236. doi:10.1038/sj.npp.1301419
65. Zingg HH, Laporte SA (2003) The oxytocin receptor. Trends Endocrinol Metabol 14: 222-227. doi:http://dx.doi.org/10.1016/S1043-2760(03)00080-8